Vetirus Pharmaceuticals

What Vetirus Pharmaceuticals does

Vetirus Pharmaceuticals is a privately held, Florida-incorporated LLC (Vetirus, LLC) that operates as a multinational veterinary-focused biopharmaceutical company developing biologics, regenerative medicine, and immunotherapy products for companion animals (dogs, cats, and horses). The company maintains a North American headquarters in Naples, Florida (4280 Tamiami Trail East, Suite 302) and a European office in London (2 Royal College Street, NW1 0NH), with a brand portfolio spanning nine trademarked SKUs: VIVINIAS (canine dental), REBOUND PRP and PRF (FDA-registered regenerative medicine), PREMVILA (feline dental), TRIVISMA (topical dermatology), EXENIAS (canine sarcopenia), ZONEXIAS HEMORAPID (surgical glue), EMVISMA (developed with University of Cambridge's Prof. Paul Freeman), ARCHERAS (hypoallergenic nutrition), and IPVM-173 (a proprietary IgG-degrading protease developed with Immune Propulsion for veterinary oncology). The IPVM-173 platform targets large mass tumors by cleaving the IgG hinge region to amplify the host's anti-tumor immune response without added side effects, with preclinical evidence indicating IdeS-family enzymes can boost monoclonal antibody potency in oncology models.

The company generates revenue through a dual-channel model: direct-to-consumer e-commerce via vetirus.com and simvasta.com (with US-currency pricing and a 60-day return policy) targeting pet owners, and a B2B veterinary practice channel supplying therapeutic and regenerative products to veterinary professionals and oncology specialists. A secondary licensing and co-development revenue stream flows from strategic partnerships such as the April 2026 Immune Propulsion agreement, under which Vetirus holds exclusive veterinary commercialization rights to IPVM-173 while Immune Propulsion retains human-medicine rights. Distribution is global in scope but currently serves the U.S. and UK, with marketing driven primarily by the company website, newsroom/earned media, and LinkedIn rather than large-scale field sales or paid acquisition. CEO Robert N. Jordan leads the company, which has executed at least two undisclosed acquisitions in 2025 (Enso Discoveries and a Kansas biotech) as part of an inorganic capability buildout.

Name

Vetirus Pharmaceuticals

Legal name

Vetirus, LLC

Website

https://vetirus.com

Company type

Private

Operating status

Operating

Short description

Vetirus Pharmaceuticals is a privately held multinational veterinary biopharmaceutical company that develops and sells biologics, regenerative medicine, and immunotherapy products (including FDA-registered REBOUND PRP/PRF and the IPVM-173 oncology platform) for companion animals via DTC e-commerce and B2B veterinary channels.

Ownership category

akta.pro rank

Product category

Veterinary Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pet and Pet Supplies Retailers (45991), Veterinary Services (54194)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

akta.pro secondary industries

Oncology & Specialty Therapeutics (HLAMAEAJ), Dermatology & Allergy Drugs (HLAMAEAH), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary biopharmaceuticals
• Companion animal health
• Animal oncology therapeutics
• Regenerative animal medicine
• Veterinary biologics

Headquarters

HQ city

Naples

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Biopharmaceutical and Wellness Product Sales: Vetirus generates revenue through the sale of biopharmaceutical and wellness products for companion animals, including dental health products, regenerative medicine, dermatology treatments, and surgical products, sold directly via e-commerce (vetirus.com, simvasta.com) and potentially through veterinary channel partners.
2. Licensing and Co-Development Revenue: Through strategic partnerships such as with Immune Propulsion, Vetirus leads development, regulatory advancement, and commercialization of therapeutic products for veterinary use, generating revenue through product commercialization rights and potential milestone payments.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Vetirus Pharmaceuticals develops and commercializes biologic and regenerative therapies for companion animals (dogs, cats, and horses). Its portfolio spans oncology (IgG-degrading protease IPVM-173), FDA-registered regenerative medicine (REBOUND PRP/PRF), dental health (VIVINIAS, PREMVILA), dermatology (TRIVISMA), sarcopenia treatment (EXENIAS), surgical adhesives (ZONEXIAS HEMORAPID), and nutritional supplements (ARCHERAS), sold through veterinary practice channels and proprietary e-commerce storefronts.

Product overview

Vetirus Pharmaceuticals is a multinational veterinary-focused biopharmaceutical company that develops innovative therapies for companion animal health. The company's portfolio includes a diverse range of products spanning multiple therapeutic areas: dental health products (VIVINIASTM, PREMVILATM) addressing periodontal infections and oral bacteria; regenerative medicine (REBOUNDTM PRP and PRF) for tissue healing; dermatology/topical treatments (TRIVISMATM) for skin infections; surgical products (ZONEXIAS HEMORAPIDTM) for wound closure; oncology (IPVM-173TM) leveraging IgG-degrading protease technology; and specialty therapeutics (EXENIASTM for sarcopenia, EMVISMATM developed with University of Cambridge). Additionally, ARCHERASTM offers nutritional supplements in the form of hypoallergenic dog treats. The company operates across North America (Naples, FL) and Europe (London, UK).

Differentiator

Problem solved

Functional benefit

Brands

• VIVINIASTM: All natural triple-action dental product for canine oral bacteria defense
• REBOUNDTM PRP and PRF
• PREMVILATM
• TRIVISMATM
• EXENIASTM
• ARCHERASTM
• ZONEXIASTM HEMORAPIDTM
• EMVISMATM
• IPVM-173TM
• Simvasta

Products and services

• VIVINIAS™ An all-natural triple-action dental product designed to support defense against canine oral bacteria associated with chronic periodontal infections, sold primarily through e-commerce to pet owners.
• REBOUND™ PRP and PRF FDA-registered regenerative medicine solution delivering high-performance Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) for tissue regeneration in canines, felines, and horses, distributed to veterinary practices.
• PREMVILA™ Feline dental chew formulated for optimal dental and gum health that naturally reduces production of inflammatory cytokines along the gumline.
• TRIVISMA™ Non-synthetic topical formula that treats bacterial and fungal skin infections, itchy skin, and hot spots in companion animals.
• IPVM-173™ Proprietary IgG-degrading protease being developed to treat large mass tumors in companion animals by cleaving the hinge region of IgG antibodies to paradoxically enhance the host's own anti-tumor immune response.
• ZONEXIAS HEMORAPID™ Revolutionary surgical glue characterized by unmatched speed, strength, and water defiance for wound closure in veterinary surgical procedures.
• EMVISMA™ Veterinary product developed in exclusive partnership with Prof. Paul Freeman of the University of Cambridge, Queen's Veterinary School Hospital.
• EXENIAS™ Therapeutic product that treats canine sarcopenia (loss of muscle mass) by reducing production of inflammatory cytokines.
• ARCHERAS™ Hypoallergenic dog treat with high digestibility, non-GMO ingredients, and 100% hydrolyzed protein, specially formulated for all life stages.

Quantifiable outcome

• Preclinical data demonstrate that IdeS-family enzymes can significantly boost the potency of monoclonal antibodies in oncology models.
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Immune Propulsion, LLCcoreStrategic or Co-development Partner · 16 April 2026Vetirus Pharmaceuticals partnered with Immune Propulsion to develop and commercialize IPVM-173, a proprietary IgG-degrading protease designed to treat large mass tumors in companion animals. Under the agreement, Vetirus leads development, regulatory advancement, and commercialization exclusively for veterinary use. Immune Propulsion continues advancing the platform for human medicine. Initial studies are expected to begin immediately, with the goal of bringing the therapy to veterinary practices in the near term.
• Prof. Paul Freeman, University of Cambridge, Queen's Veterinary School HospitalcoreStrategic or Co-development PartnerVetirus developed EMVISMA™ in exclusive partnership with Prof. Paul Freeman of the University of Cambridge, Queen's Veterinary School Hospital, representing a key academic collaboration for product development.
• Accord Animal HealthminorStrategic or Co-development PartnerAccord Animal Health launched Vivinicord Chews® for dogs, a triple-action dental product related to Vetirus's product category, mentioned in Vetirus's newsroom coverage of industry news. Nature of relationship appears to be industry news coverage rather than formal partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Virbac: Virbac is a France-based global veterinary pharmaceutical company focused on companion animal health, including dermatology, dental, and specialty therapeutics. It is closely comparable to Vetirus's portfolio mix of dental, dermatology, and specialty companion-animal products, though with a more established international commercial footprint.
• Dechra Pharmaceuticals: Dechra is a UK-based veterinary pharmaceutical company specializing in companion animal therapeutics, with strong positions in dermatology, endocrine, and specialty therapies. Its specialty pharmaceutical focus and London-area base make it highly comparable to Vetirus's European operations and therapeutic mix.
• Kindred Biosciences: Kindred Biosciences is a veterinary biopharmaceutical company developing biologics and small-molecule therapeutics for companion animals, with particular focus on unmet medical needs. It is highly comparable to Vetirus's biologics and specialty therapeutics pipeline targeting dogs and cats, including oncology-adjacent indications.
• Parnell Pharmaceuticals Holdings: Parnell is a specialty veterinary pharmaceutical company developing and commercializing therapeutics for companion animals and livestock, with emphasis on differentiated formulations and injectables. It is comparable to Vetirus as a smaller, specialty-focused veterinary pharmaceutical company with companion-animal therapeutics as a core franchise.
• VetStem Biopharma: VetStem Biopharma is a veterinary regenerative medicine company specializing in stem cell and PRP-based therapies for companion animals, particularly dogs, cats, and horses. It is directly comparable to Vetirus's REBOUND PRP/PRF regenerative medicine franchise and operates in the same specialty veterinary channel.
• Aratana Therapeutics: Aratana Therapeutics was a veterinary biopharmaceutical company focused on developing and commercializing innovative therapeutics for companion animals, with notable oncology and specialty therapeutic franchises. It is closely comparable to Vetirus's biologics and specialty therapeutics focus, though it has been acquired and consolidated into a larger parent.
• Vetoquinol: Vetoquinol is a French veterinary pharmaceutical company focused on companion animal health, including dermatology, dental care, and specialty therapeutics. It is comparable to Vetirus in product category mix (especially dental and dermatology) and in serving the same veterinary channel customers.

Broad incumbents

• Elanco Animal Health: Elanco is a major global animal health company with a diversified portfolio of therapeutics, vaccines, and parasiticides for both companion animals and livestock. It competes with Vetirus across pharmaceutical preparations, particularly in dermatology, oncology, and specialty companion-animal therapeutics.
• Zoetis: Zoetis is the world's largest animal health company, offering pharmaceuticals, vaccines, diagnostics, and biologics across companion and livestock animals. It is directly comparable to Vetirus as a broad incumbent in the veterinary biopharmaceutical space, though with vastly greater scale and a fully commercialized pipeline.
• IDEXX Laboratories: IDEXX is the dominant companion-animal diagnostics company and has expanded into practice software, reference labs, and select therapeutics. It serves the same veterinary customer base as Vetirus and represents the standard enterprise benchmark that veterinary practices evaluate technology and pharmaceutical partners against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/vetirus

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetirus Pharmaceuticals